Neurology:帕金森病患者步态障碍,补偿策略知多少

2022-08-30 Freeman MedSci原创

支持在PD的步态康复中使用补偿策略,但强调了个性化方法的重要性

在帕金森病(PD)患者中,步态障碍是常见的和致残的。步幅缩短、步态变异性增加和手臂摆动减少是典型发生在帕金森病患者身上的连续步态障碍的例子。随着疾病的发展,偶发的步态障碍,包括步态冻结(FOG)和晕厥,也可能发挥作用。步态障碍的存在往往会导致跌倒和与跌倒有关的伤害,并严重影响功能活动能力、独立性和生活质量。

图1: 论文封面图

由于多巴胺能药物治疗和深部脑刺激通常对步态障碍只有适度的影响,应用补偿策略已成为PD步态康复的一个重要部分。这些策略通常是由PD患者自创的,包括一系列的 "迂回",以克服步态障碍和改善功能移动。例如,在跟随音乐节拍行走时改善步态,边走边数,倒着走,爬楼梯,或在有特定视觉图案的地板上行走。虽然经常在FOG的背景下应用,但补偿策略也能改善连续步态缺陷。

到目前为止,PD的补偿策略通常以案例报告的形式报道。除了外部提示(如有节奏的听觉刺激),这些策略的疗效很少以系统的方式被调查。2019年,提出了一个由七类不同策略组成的综合框架:外部提示、内部提示、改变平衡要求、改变心理状态、行动观察或运动想象、采用新的行走模式,以及替代行走的方法。这一框架成为对4,324名患有PD和步态障碍的人进行补偿策略认知的大规模调查的基础,提供了补偿策略有效的第四级证据。然而,该研究也证实,具体策略的功效因人而异,强调了需要采取单独定制的方法。我们仍然没有充分了解这些策略的基本工作机制是什么,以及哪些病人的特征可能与各种补偿策略的个人疗效有关。这阻碍了医护人员提供亟需的个性化步态康复的能力。

藉此,荷兰奈梅亨大学的Anouk Tosserams等人,评估了五类不同补偿策略的功效:外部提示、内部提示、动作观察、运动想象和采用新的行走模式。

主要目的:
(1)建立患者对不同策略的功效和可用性的看法;
(2)量化策略对时空步态参数的功效
(3)探索特定策略对步态的影响是否与某些患者特征有关。

他们招募了PD患者和自我报告的失能步态障碍者参加这项基于实验室的对象内研究。临床测量包括:问卷调查(NFOG-Q、VMIQ-2、GMSI)、认知评估(ANT、MoCA、Brixton)和体格检查(MDS-UPDRS III、Mini-BEST、串联步态、快速转向测试)。

步态评估包括在6米长的走道上进行6次3分钟的连续行走试验。

试验包括:1)基线步态;2)外部提示;3)内部提示;4)动作观察;5)运动想象;和6)采用新的行走模式。使用三维运动捕捉分析获得时空步态参数。与基线步态相比,策略的有效性由步态变异性的变化决定。使用回归分析探讨了相关的患者特征。

101名参与者(50名男性;中位[范围]年龄:66[47-91]岁)被纳入。

图2:论文结果图

不同策略的效果在参与者中差异很大。虽然基线变异性较高的参与者使用补偿策略有较大的改善,但没有步态冻结、MDS-UPDRS III评分较低、平衡能力较高和定向注意力表现较好的参与者在步态变异性方面也有较大改善。

更高的MoCA分数与外部提示的更大作用有关。

该研究的重要意义在于发现了:支持在PD的步态康复中使用补偿策略,但强调了个性化方法的重要性。即使是高步态变异性的患者也能通过应用补偿策略而得到改善,但要从补偿策略中获得最佳效益,似乎需要一定的认知和功能储备水平。

 

原文出处:
Tosserams A, Keijsers N, Kapelle W, et al. Evaluation of Compensation Strategies for Gait Impairment in Patients With Parkinson Disease. _Neurology_. Published online August 25, 2022:10.1212/WNL.0000000000201159. doi:[10.1212/WNL.0000000000201159](https://doi.org/10.1212/WNL.0000000000201159)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1742015, encodeId=e0e01e42015ba, content=<a href='/topic/show?id=5681632e84e' target=_blank style='color:#2F92EE;'>#步态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63278, encryptionId=5681632e84e, topicName=步态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f034999566, createdName=xxxx1061, createdTime=Thu Oct 27 12:43:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745659, encodeId=a2ca1e45659d5, content=<a href='/topic/show?id=48a66328640' target=_blank style='color:#2F92EE;'>#步态障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63286, encryptionId=48a66328640, topicName=步态障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fcb35536691, createdName=meichuangyi, createdTime=Sun Jul 23 03:43:55 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001922, encodeId=bde1200192258, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Sep 12 05:43:55 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757462, encodeId=c0571e57462c3, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Thu Mar 16 21:43:55 CST 2023, time=2023-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573975, encodeId=605b15e397568, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Sep 01 02:43:55 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
    2022-10-27 xxxx1061
  2. [GetPortalCommentsPageByObjectIdResponse(id=1742015, encodeId=e0e01e42015ba, content=<a href='/topic/show?id=5681632e84e' target=_blank style='color:#2F92EE;'>#步态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63278, encryptionId=5681632e84e, topicName=步态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f034999566, createdName=xxxx1061, createdTime=Thu Oct 27 12:43:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745659, encodeId=a2ca1e45659d5, content=<a href='/topic/show?id=48a66328640' target=_blank style='color:#2F92EE;'>#步态障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63286, encryptionId=48a66328640, topicName=步态障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fcb35536691, createdName=meichuangyi, createdTime=Sun Jul 23 03:43:55 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001922, encodeId=bde1200192258, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Sep 12 05:43:55 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757462, encodeId=c0571e57462c3, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Thu Mar 16 21:43:55 CST 2023, time=2023-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573975, encodeId=605b15e397568, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Sep 01 02:43:55 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1742015, encodeId=e0e01e42015ba, content=<a href='/topic/show?id=5681632e84e' target=_blank style='color:#2F92EE;'>#步态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63278, encryptionId=5681632e84e, topicName=步态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f034999566, createdName=xxxx1061, createdTime=Thu Oct 27 12:43:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745659, encodeId=a2ca1e45659d5, content=<a href='/topic/show?id=48a66328640' target=_blank style='color:#2F92EE;'>#步态障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63286, encryptionId=48a66328640, topicName=步态障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fcb35536691, createdName=meichuangyi, createdTime=Sun Jul 23 03:43:55 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001922, encodeId=bde1200192258, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Sep 12 05:43:55 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757462, encodeId=c0571e57462c3, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Thu Mar 16 21:43:55 CST 2023, time=2023-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573975, encodeId=605b15e397568, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Sep 01 02:43:55 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
    2022-09-12 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1742015, encodeId=e0e01e42015ba, content=<a href='/topic/show?id=5681632e84e' target=_blank style='color:#2F92EE;'>#步态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63278, encryptionId=5681632e84e, topicName=步态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f034999566, createdName=xxxx1061, createdTime=Thu Oct 27 12:43:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745659, encodeId=a2ca1e45659d5, content=<a href='/topic/show?id=48a66328640' target=_blank style='color:#2F92EE;'>#步态障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63286, encryptionId=48a66328640, topicName=步态障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fcb35536691, createdName=meichuangyi, createdTime=Sun Jul 23 03:43:55 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001922, encodeId=bde1200192258, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Sep 12 05:43:55 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757462, encodeId=c0571e57462c3, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Thu Mar 16 21:43:55 CST 2023, time=2023-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573975, encodeId=605b15e397568, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Sep 01 02:43:55 CST 2022, time=2022-09-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1742015, encodeId=e0e01e42015ba, content=<a href='/topic/show?id=5681632e84e' target=_blank style='color:#2F92EE;'>#步态#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63278, encryptionId=5681632e84e, topicName=步态)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=76f034999566, createdName=xxxx1061, createdTime=Thu Oct 27 12:43:55 CST 2022, time=2022-10-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1745659, encodeId=a2ca1e45659d5, content=<a href='/topic/show?id=48a66328640' target=_blank style='color:#2F92EE;'>#步态障碍#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63286, encryptionId=48a66328640, topicName=步态障碍)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7fcb35536691, createdName=meichuangyi, createdTime=Sun Jul 23 03:43:55 CST 2023, time=2023-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001922, encodeId=bde1200192258, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Mon Sep 12 05:43:55 CST 2022, time=2022-09-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1757462, encodeId=c0571e57462c3, content=<a href='/topic/show?id=058e4852e63' target=_blank style='color:#2F92EE;'>#帕金森病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48527, encryptionId=058e4852e63, topicName=帕金森病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a17f37322741, createdName=ms6832696159214430, createdTime=Thu Mar 16 21:43:55 CST 2023, time=2023-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573975, encodeId=605b15e397568, content=<a href='/topic/show?id=6b3348526a0' target=_blank style='color:#2F92EE;'>#帕金森病患#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=48526, encryptionId=6b3348526a0, topicName=帕金森病患)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=73fe15977481, createdName=saikp, createdTime=Thu Sep 01 02:43:55 CST 2022, time=2022-09-01, status=1, ipAttribution=)]

相关资讯

JAMA Netw Open:做好这两点,帕金森病患者全因死亡风险骤降65%!

 JAMA Netw Open:饮食和身体活动与帕金森病成人全因死亡率的关系

Movement disorders:湘雅医院:狗狗嗅一嗅,就能诊断帕金森病?

使用嗅探犬进行测试可能是一种有用的、无创的、快速的和具有成本效益的方法

Movement disorders:帕金森病的运动和认知代谢网络之间的关系

通过delta量化的PDRP优势,可以检测出PD患者的功能障碍从运动网络向认知网络的扩散

Movement disorders:PM2.5,或可诱发帕金森病

M2.5触发了α-Syn的病理学和PD的发病

JAMA子刊:高翔教授发现吃得对会运动,帕金森死亡率能降一半!

无论是健康饮食还是积极锻炼,都能充分保护帕金森患者的寿命。

Movement disorders:葡萄糖苷酶变体携带者和家族性帕金森病的性别频率差异

GBA PD总体上存在的男性性别优势在GBA变异的严重程度上并不一致,

拓展阅读

AAN 2024大会盛况回顾,带您领略神经病学新高度!

作为神经科医生,您一定对AAN 2024年大会充满期待。我们为您精心整理了大会内容解读,包括最新研究成果、临床实践经验和未来发展趋势等,让您足不出户就能领略到大会的精彩盛况!点击立即查看别错过!

AAN 2024:突触核蛋白皮肤活检在帕金森病的初步诊断的临床实践

帕金森病早期准确诊断是一项尚未满足的重大需求,这对于早期干预和预后改善有着重要的影响。

Nature Medicine:重塑帕金森病治疗前景:Prasinezumab在早期帕金森病快速进展亚型中的疗效分析

文章探讨了Prasinezumab这种单克隆抗体在早期帕金森病中的潜在的治疗作用。

【帕金森病专题分享】探索帕金森病进展及诊疗全攻略

帕金森病日来临之际,我们特别推出了帕金森病专题系列文章。无论你是初入此领域的新手,还是经验丰富的专家,这里都有你需要的知识和信息。点击立即阅读,共同提升帕金森病诊疗水平!

话题:帕金森病的真相你了解多少?

我们欢迎各位老师,学者们在下方评论区共同探讨帕金森病的各个方面,包括但不限于:帕金森病的介绍、早期症状、体征、预防等都可一起分享出来。

好文推荐 | 帕金森病睡眠障碍结构特征及其影响因素的临床研究

探讨帕金森病(PD)患者睡眠障碍的发生率、睡眠结构特征、影响因素。

2024 NICE 诊断指南:帕金森病远程监测设备 [DG51]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2024-01-25

2023 NICE 技术鉴定指南:左旋多巴/卡比多巴组合治疗伴有运动症状的晚期帕金森病[TA934]

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2023-11-29

帕金森病患者睡眠障碍评估与护理干预的最佳证据总结

浙江中医药大学护理学院 · 2023-08-10

早中期帕金森病患者运动管理的最佳证据总结

山东第一医科大学附属省立医院老年神经内科 · 2023-05-10